Novo Nordisk A/S
NVOHealthcareNASDAQDrug Manufacturers - General · Last scanned May 30, 2026
Scan Results
Daily timeframeNovo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. With a market capitalization of $201.95B, it sits in mega-cap territory. It operates through two segments, Obesity and Diabetes Care, and Rare Disease.
Market Cap
$201.95B
Beta
0.35
P/E (TTM)
10.67
P/E (Fwd)
13.71
EPS (TTM)
$4.27
EPS (Fwd)
$3.32
ROE
71.4%
ROA
19.3%
Cash
$21.63B
Total Debt
$146.38B
Free CF
-$12.04B
52W Change
-37.4%
Annual Financials
Cash vs Debt
On the balance sheet, NVO has $21.63B in cash with $146.38B in obligations. The ability to service this debt comfortably depends on continued operational cash generation. The company is burning cash, with free cash flow at -$12.04B. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of 71.4% points to exceptionally high capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Return on assets of 19.2% further supports the picture of efficient asset utilization. Revenue has grown from $176.95B (2022) to $309.06B (2025), reflecting a 75% increase over the period.
With a beta below 0.7, Novo Nordisk A/S typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. The debt-to-cash ratio suggests meaningful leverage on the balance sheet, a factor worth monitoring if credit conditions tighten. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Novo Nordisk A/S's trajectory.